An observational study in Coronary Disease, sponsored by Robocath. Recruiting at 8 sites in 6 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by Robocath · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Coronary Disease with a site in France — 3 open to participants now, 5 under way, none of them phase 3. Coronary Disease · France.
Among the 58 studies in Coronary Disease with a site in France, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2023, is one of 15 observational ones, and was the 53rd registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →3 of the 58 studies in Coronary Disease with a site in France are open now. Recruiting first, the newest first:
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
University Hospital, Montpellier · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 9 · Phase 4 6
First in 1998; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is below the median of 916 across 478 observational studies indexed under Coronary Disease.
Median enrollment 300 across the 43 interventional studies, 294 across the 15 observational. Of the 48 that completed or were terminated, 12 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 58 have an industry lead sponsor. The 10 most frequent:
Robocath is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Robocath has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 58 studies in Coronary Disease with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of the CHANGE registry is the evaluation of the real-world performance and safety profile of the R-One System in PCI.
The R-One system is a class "IIb" CE marked medical device designed to remote deliver and manipulate coronary guidewires and stent/balloon devices during Percutaneous Coronary Intervention (PCI). The system comprises the R-One Robotic Platform used in combination with two accessories, the Mobile Radioprotection Screen and a sterile and single-use R-One Consumable Kit. The R-One is not autonomous and operates only under the operator's commands.
This study is a single-arm, open-label, multi-center registry.
The CHANGE registry, part of the ROBOCATH's post-market clinical follow-up activities, is a real world study aiming to confirm the safety and performance, including the clinical benefit, of the R-One robotic systems medical device.
500 patients with coronary artery disease and with clinical indication for PCI will be recruited in up to Up to 15 centers distributed in Europe and South Africa.
Subjects with coronary artery disease and a clinical indication for PCI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with coronary artery disease and a clinical indication for PCI
Device: Robotic-assisted PCI
Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
Clinical success
Less than 30% residual stenosis (visual estimate) post PCI in the lesion(s) treated with the R-One System, without in-hospital major adverse cardiac events (MACE).
Time frame: From Day 0 to Day 3
Technical success
Absence of any unplanned manual assistance or conversion to manual PCI for procedural completion
Time frame: During procedure
Radiation exposure for the patient
Dose (DSP and Air Kerma) measured by the imaging system during the procedure.
Time frame: During procedure
Overall Procedure Time
Defined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.
Time frame: During procedure
Overall contrast volume
Total volume of contrast (mL) used during the procedure.
Time frame: During procedure
Radiation exposure for the operator
Cumulative dose the operator receives as recorded from an electronic pocket dosimeter during the procedure.
Time frame: During procedure
Fluoroscopy Time
Total fluoroscopy utilized during the procedure as recorded by an Imaging System.
Time frame: During procedure
Safety event occurrence
Medical device's safety event occurrence
Time frame: From Day 0 to Day 3
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for May 2026, 35 months after the start.
Of 154 observational studies under Coronary Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 123. This study's planned 35 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Robocath